Baird raised the firm’s price target on Labcorp to $241 from $239 and keeps an Outperform rating on the shares. The firm noted management commentary at an investor conference was confident, reiterating recently communicated LRP and strategic focus and they reiterated prior 3Q23 commentary, suggesting strong momentum into 2024 for Diagnostics and Central Lab volumes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LH:
- Labcorp initiated with an Equal Weight at Barclays
- SomaLogic corrects ‘Madryn Asset Management’s misleading disclosure’
- SomaLogic shareholder says company ran ‘incomplete’ review of alternatives
- Labcorp and Legacy Health Finalize Comprehensive Laboratory Relationship
- Labcorp price target raised to $261 from $259 at JPMorgan
